65220-86-2

Usage

Uses

Used in Chemical Research:
1-(trifluoroacetyl)piperidin-4-one is used as a research compound for exploring its chemical properties and potential applications in the field of organic chemistry. Its unique structure with a trifluoroacetyl group provides opportunities for studying its reactivity and interactions with other molecules.
Used in Synthesis:
1-(trifluoroacetyl)piperidin-4-one is used as a synthetic intermediate in the preparation of more complex organic molecules. Its trifluoroacetyl group can be a key functional group in the synthesis of various pharmaceuticals, agrochemicals, or other specialty chemicals, depending on the specific requirements of the target molecule.
Used in Material Safety Data Sheets (MSDS):
1-(trifluoroacetyl)piperidin-4-one is used as a reference compound in Material Safety Data Sheets (MSDS) to document its detailed properties such as chemical stability, reactivity, and health risks. This information is crucial for ensuring safe handling, storage, and disposal of the compound in research and industrial settings.

InChI:InChI=1/C7H8F3NO2/c8-7(9,10)6(13)11-3-1-5(12)2-4-11/h1-4H2

Upstream product

• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 93343-02-3 N-trifluoroacetyl-4-hydroxypiperidine 
• 41979-39-9 4-piperidone hydrochloride 
• 40064-34-4 4-piperidone monohydrochloride monohydrate 
• 407-25-0 trifluoroacetic anhydride 

Downstream Products

• 176910-36-4 2,2,2-trifluoro-1-(1,4-dioxa-8-azaspiro[4.5]decan-8-yl)ethan-1-one 
• 359881-71-3 2-(4-chlorophenyl)-N-(4-methylbenzyl)-N-(1-ethylpiperidin-4-yl)acetamide hydrochloride 
• 359879-55-3 N-((3-hydroxy-4-methylphenyl)methyl)-4-amino-1-methylpiperidine 
• 359879-02-0 2-(4-Methoxyphenyl)-N-(4-methylbenzyl)-N-[1-(2-methylthiazol-4-ylmethyl) piperidin-4-yl] acetamide 
• 732977-32-1 2-(4-Methoxyphenyl)-N-(4-methylbenzyl)-N-(1-trifluoroacetylpiperidin-4-yl) acetamide 

Relevant academic research and scientific papers

SALTS OF AN LSD1 INHIBITOR AND PROCESSES FOR PREPARING THE SAME

The present invention relates to processes and intermediates for preparing 3-(cyanomethyl)-3-(4-{[(1R,2S)-2-phenylcyclopropyl]amino}piperidin-1-yl)azetidine-1-sulfonamide, and salts and solid forms thereof, which selectively modulate demethylase. Particular embodiments contemplate compounds and disease indications amenable to treatment by modulation of lysine specific demethylase-1 (LSD1).

LSD1 Inhibitors

The present invention relates to compounds that inhibit LSD1 activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.

AZACYCLIC COMPOUNDS

Compounds and methods are provided for the treatment of disease conditions in which modification of serotonergic receptor activity has a beneficial effect. In the method, an effective amount of a compound is adminstered to a patient in need of such treatment.

ACRYLAMIDE COMPOUNDS AND THE USE THEREOF

The invention relates to acrylamide compounds of Formula I mentioned below. The invention is also directed to the use compounds of Formula I to treat or prevent a disorder responsive to the blockade of calcium channels, and particularly N-type calcium cha

N-SUBSTITUTED PIPERIDINE DERIVATIVES AS SEROTONIN RECEPTOR AGENTS

Disclosed herein are isolated forms of the compounds of Formula (I), (II), (III), (IV) and (V), or a pharmaceutically acceptable salt, prodrug, hydrate, solvate, polymorph, or ester thereof. Also disclosed are methods of inhibiting an activity of a serotonin receptor, methods inhibiting an activation of a serotonin receptor, and methods of alleviating or treating various disease conditions and side effects.

Nanoscale molecular rods with a new building block for solubility enhancement

(Chemical Equation Presented) A new building block bearing a [1,3]dioxolo[4,5-f][1,3]benzodioxole core was developed to enhance the solubility of molecular rods by lateral alkyl chains. On incorporation in molecular rods with oligospiroketal structure, the straight geometry is retained, which was concluded from the X-ray crystal structure analysis of one of the rods. The determination of the solubility of a collection of rods bearing this building block revealed that already a butyl group efficiently hinders the aggregation of the rods and consequently causes a considerable enhancement of the solubility. Piperidine rings are located at the ends of the rods, which offer the opportunity for versatile functionalization. Thus, an N,N′-bis(azidoacetyl)-functionalized rod was prepared, which could serve as rigid linkage, initiated by a "Click" reaction.

USE OF 4-AMINO-PIPERIDINES FOR TREATING SLEEP DISORDERS

Inverse agonists and antagonists of serotonin receptors are disclosed for use in treating sleep disorders such as insomnia, and specifically sleep maintenance insomnia. The compound increase slow wave sleep, decrease the number of awakenings after sleep onset, and decrease the time awake after sleep onset.

PI3 KINASES

The invention relates to the novel compounds of formula (1), which, due to their pharmaceutical effect as PI3 kinase modulators, are suitable for use in the therapy and treatment of inflammatory or allergic diseases. Examples of these diseases are inflammatory and allergic respiratory diseases, inflammatory diseases of the gastro-intestinal system and of the locomotor apparatus, inflammatory and allergic skin diseases, inflammatory ophthalmic diseases, diseases of the nasal mucosa, inflammatory or allergic autoimmune reactive conditions, or renal inflammations.

N-SUBSTITUTED PIPERIDINE DERIVATIVES AS SEROTONIN RECPTOR AGENTS

Disclosed herein are compounds of Formula I, or a pharmaceutically acceptable salt, amide, ester, or prodrug thereof. Also disclosed are methods of inhibiting an activity of a monoamine receptor comprising contacting the monoamine receptor or a system containing the monoamine receptor with an effective amount of one or more of the compounds of Formula I. Disclosed are also methods of inhibiting an activation of a monoamine receptor comprising contacting the monoamine receptor or a system containing the monoamine receptor with an effective amount of one or more of the compounds of Formula I. Furthermore, methods of treating psychotic disease using a compound of Formula I are disclosed.

Azacyclic compounds

Compounds and methods are provided for the treatment of disease conditions in which modification of serotonergic receptor activity has a beneficial effect. In the method, an effective amount of a compound is adminstered to a patient in need of such treatment.